Pfizer Whistleblower Sinks Vaccine Trial Integrity

Pfizer Whistleblower Sinks Vaccine Trial Integrity by Dr. Joseph Mercola

STORY AT-A-GLANCE

  • According to a whistleblower who worked on Pfizer’s Phase 3 COVID jab trial, data were falsified, patients were unblinded, the company hired poorly trained people to administer the injections, and follow-up on reported side effects lagged way behind
  • Brook Jackson was the regional director of Ventavia Research Group, a research organization charged with testing Pfizer’s COVID jab at several sites in Texas. Jackson repeatedly “informed her superiors of poor laboratory management, patient safety concerns, and data integrity issues,” and when her concerns were ignored, she finally filed a complaint with the U.S. Food and Drug Administration
  • The FDA did not follow up on her complaint. Ventavia was not one of the nine trial locations audited, and Pfizer did not bring any of those issues up when applying for emergency use authorization for its COVID shot
  • Documentation shared by Jackson shows a Ventavia executive had identified three site staff members who had falsified data
  • After being notified of Jackson’s complaints, Pfizer contracted Ventavia to conduct four additional trials — one for COVID shots in children and young adults, one for the COVID jab in pregnant women, a booster shot trial, and an RSV vaccine trial

Yet again, mainstream media have completely ignored what should have been front-page news. According to a whistleblower who worked on Pfizer’s Phase 3 COVID jab trial in the fall of 2020, data were falsified, patients were unblinded, the company hired poorly trained people to administer the injections, and follow-up on reported side effects lagged way behind.

What makes the media’s silence all the more remarkable is that this revelation was published in The British Medical Journal. Paul Thacker, investigative journalist for The BMJ, writes in his November 2, 2021, report:1

“Revelations of poor practices at a contract research company helping to carry out Pfizer’s pivotal covid-19 vaccine trial raise questions about data integrity and regulatory oversight …

[F]or researchers who were testing Pfizer’s vaccine at several sites in Texas during that autumn, speed may have come at the cost of data integrity and patient safety … Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding.”

As noted by Bill Bruckner for transparimed.org:2

“Editors’ widespread failure to pick up on the story is deeply problematic. First and foremost, it lets the U.S. Food and Drug Administration off the hook for what appear to be severe lapses in regulatory oversight over this trial … Where are the media outlets questioning the FDA about its oversight processes? Where are the politicians calling for an enquiry? …

Second, it lets Pfizer off the hook for apparently failing to adequately oversee the operations of its subcontractor … Where are the media outlets questioning Pfizer about its oversight and quality assurance processes? …

Third, it undermines confidence in democratic institutions and public health bodies because it gives citizens … the impression that mainstream media are deliberately ignoring a big story in order to avoid fueling vaccine hesitancy.”

So far, this story has been largely confined to the alternative news media. You’ll find a selection of video reports covering the whistleblower’s testimony in the sections below.

Research Organization Falsified Data in Pfizer Trial

The whistleblower in question is Brook Jackson, a former regional director of Ventavia Research Group, a research organization charged with testing Pfizer’s COVID jab at several sites in Texas.

Jackson repeatedly “informed her superiors of poor laboratory management, patient safety concerns and data integrity issues,” Thacker writes, and when her concerns were ignored, she finally called the U.S. Food and Drug Administration and filed a complaint via email.

Jackson was fired later that day after just two weeks on the job. According to her separation letter, management decided she was “not a good fit” for the company after all. She has provided The BMJ with “dozens of internal company documents, photos, audio recordings and emails” proving her concerns were valid. According to Jackson, this was the first time she’d ever been fired in her 20-year career as a clinical research coordinator. Thacker explains:3

Continue Reading / Mercola >>>

Related posts